Literature DB >> 8182030

Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.

L Z Goldani, A M Sugar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8182030     DOI： 10.1093/jac/33.2.369

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

4.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 5.  Animal models of zygomycosis--Absidia, Rhizopus, Rhizomucor, and Cunninghamella.

Authors:  K Kamei
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

Review 6.  Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.

Authors:  Rohit Sharma; Praveen Kumar; Abdur Rauf; Ashun Chaudhary; Pradeep Kumar Prajapati; Talha Bin Emran; Clara Mariana Gonçalves Lima; Carlos Adam Conte-Junior
Journal:  Front Cell Infect Microbiol       Date:  2022-07-18       Impact factor: 6.073
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.